Share Talk - Exclusive Stock Market News and Articles
Tiziana Life Sci PLC (NASDAQ:TLSA LON:TILS) Dr Kunwar Shailubhai, CEO & CSO
July 22, 2019
 We are very pleased with the clinical activity and tolerability of Milciclib in these advanced cases of HCC. It is an important milestone to move forward with the further clinical development of Milciclib either as a single agent or in combination with other HCC drugs," said Dr Kunwar Shailubhai, CEO & CSO of Tiziana.